Bolt Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Bolt Biotherapeutics
BOLT Stock  USD 4.95  0.03  0.61%   
Analyzing historical trends in various income statement and balance sheet accounts from Bolt Biotherapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bolt Biotherapeutics' valuation are summarized below:
Gross Profit
-30.1 M
Market Capitalization
9.6 M
Enterprise Value Revenue
0.2678
Revenue
5.2 M
Earnings Share
(22.21)
There are currently one hundred twenty fundamental signals for Bolt Biotherapeutics that can be evaluated and compared over time across rivals. All traders should validate Bolt Biotherapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction.

Bolt Biotherapeutics Total Revenue

9.29 Million

Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.3 M, Interest Income of 6.3 M or Depreciation And Amortization of 1.2 M, as well as many indicators such as Price To Sales Ratio of 58.04, Dividend Yield of 0.0 or PTB Ratio of 6.75. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Bolt Stock
Check out the analysis of Bolt Biotherapeutics Correlation against competitors.
For more information on how to buy Bolt Stock please use our How to Invest in Bolt Biotherapeutics guide.

Bolt Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets142.4 M114.6 M75.9 M
Slightly volatile
Short and Long Term Debt Total17.8 M29 M9.4 M
Slightly volatile
Other Current Liabilities9.5 M10.4 M5.6 M
Slightly volatile
Total Current Liabilities16.3 M18.2 M9.4 M
Slightly volatile
Other Liabilities15.7 M14.9 M5.2 M
Slightly volatile
Property Plant And Equipment Net21.6 M28.6 M11.7 M
Slightly volatile
Accounts Payable2.6 M1.7 M1.6 M
Slightly volatile
Cash12.4 M6.5 M13.9 M
Pretty Stable
Non Current Assets Total49 M56.1 M25.4 M
Slightly volatile
Non Currrent Assets Other2.2 M1.2 M1.2 M
Slightly volatile
Other Assets1.091.15877.9 K
Pretty Stable
Cash And Short Term Investments90.5 M54.4 M48.8 M
Slightly volatile
Common Stock Shares Outstanding30.9 M43.9 M16.9 M
Slightly volatile
Liabilities And Stockholders Equity142.4 M114.6 M75.9 M
Slightly volatile
Non Current Liabilities Total43.2 M23.9 M39.9 M
Pretty Stable
Capital Lease Obligations17.8 M29 M9.4 M
Slightly volatile
Other Current Assets2.5 M2.7 M1.5 M
Slightly volatile
Total Liabilities55 M38.2 M48.8 M
Slightly volatile
Property Plant And Equipment Gross23.6 M37 M13.1 M
Slightly volatile
Total Current Assets93.3 M58.4 M50.5 M
Slightly volatile
Non Current Liabilities Other36.8 K38.7 K1.8 M
Very volatile
Net Working Capital77.1 M40.2 M41.1 M
Slightly volatile
Short Term Debt2.3 M2.6 M1.2 M
Slightly volatile
Property Plant Equipment19.5 M32.8 M12.3 M
Slightly volatile
Current Deferred Revenue2.2 M3.5 M1.4 M
Slightly volatile
Net Receivables692.5 K1.3 M500.5 K
Slightly volatile
Deferred Long Term Liabilities1.9 M2.1 M2.3 M
Slightly volatile

Bolt Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income6.3 M6 M1.7 M
Slightly volatile
Interest Income6.3 M6 M1.7 M
Slightly volatile
Depreciation And Amortization1.2 M2 M789.6 K
Slightly volatile
Selling General Administrative15.5 M21.2 M9 M
Slightly volatile
Other Operating Expenses70.3 M92.8 M41.4 M
Slightly volatile
Research Development54 M66.1 M31.7 M
Slightly volatile
Cost Of Revenue2.4 M2.5 M16.9 M
Slightly volatile
Total Operating Expenses97.5 M92.8 M28.2 M
Slightly volatile
Reconciled Depreciation1.2 M2 M789.2 K
Slightly volatile

Bolt Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.8 M8.5 M3.1 M
Slightly volatile
Begin Period Cash Flow17.8 M14.5 M10.8 M
Slightly volatile
Other Cashflows From Financing Activities92.3 K97.2 K36.1 M
Slightly volatile
Depreciation1.2 M2 M789.6 K
Slightly volatile
Capital Expenditures35.1 K36.9 K646.5 K
Pretty Stable
Issuance Of Capital Stock92.3 K97.2 K33.8 M
Very volatile
Total Cash From Financing Activities92.3 K97.2 K33.7 M
Very volatile
End Period Cash Flow13.4 M8.1 M14.6 M
Very volatile
Change To Netincome23.9 M22.8 M8.5 M
Slightly volatile
Change To Liabilities662.1 K696.9 K2.6 M
Pretty Stable
Sale Purchase Of Stock10.9 M12.3 M13.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio58.0461.120.2 K
Slightly volatile
Days Sales Outstanding60.4163.59323
Slightly volatile
Stock Based Compensation To Revenue1.051.112.4992
Pretty Stable
Capex To Depreciation0.02520.02651.1068
Pretty Stable
EV To Sales60.663.7920.2 K
Slightly volatile
Payables Turnover14.0318.549.9322
Slightly volatile
Sales General And Administrative To Revenue2.622.7618.2039
Slightly volatile
Research And Ddevelopement To Revenue8.168.5987.585
Slightly volatile
Capex To Revenue0.00580.00612.3523
Pretty Stable
Cash Per Share1.351.434.9605
Slightly volatile
Days Payables Outstanding19.3520.37579
Slightly volatile
Income Quality0.680.870.8402
Very volatile
Current Ratio4.142.884.9526
Pretty Stable
Receivables Turnover3.635.942.8905
Slightly volatile
Capex Per Share0.00120.00120.0953
Slightly volatile
Revenue Per Share0.190.180.073
Slightly volatile
Interest Debt Per Share0.460.590.3093
Slightly volatile
Debt To Assets0.240.230.0879
Slightly volatile
Operating Cycle60.4163.59323
Slightly volatile
Days Of Payables Outstanding19.3520.37579
Slightly volatile
Ebt Per Ebit1.10.991.0052
Very volatile
Quick Ratio4.142.884.9526
Pretty Stable
Cash Ratio0.50.523.1024
Slightly volatile
Days Of Sales Outstanding60.4163.59323
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0413
Slightly volatile
Fixed Asset Turnover0.290.280.097
Slightly volatile
Debt Ratio0.240.230.0879
Slightly volatile
Price Sales Ratio58.0461.120.2 K
Slightly volatile
Asset Turnover0.07290.06950.0204
Slightly volatile

Bolt Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap690.6 M469.9 M789.8 M
Slightly volatile
Enterprise Value705.6 M490.6 M800.7 M
Slightly volatile

Bolt Fundamental Market Drivers

Bolt Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bolt Biotherapeutics Financial Statements

Bolt Biotherapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue3.5 M2.2 M
Total Revenue8.8 M9.3 M
Cost Of Revenue2.5 M2.4 M
Stock Based Compensation To Revenue 1.11  1.05 
Sales General And Administrative To Revenue 2.76  2.62 
Research And Ddevelopement To Revenue 8.59  8.16 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.18  0.19 
Ebit Per Revenue(8.55)(8.98)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bolt Stock Analysis

When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY